WO2024160919 - AGENTS, COMPOSITIONS, AND METHODS FOR SUPPORTING BEHAVIOURAL DEVELOPMENT
National phase entry is expected:
Publication Number
WO/2024/160919
Publication Date
08.08.2024
International Application No.
PCT/EP2024/052415
International Filing Date
31.01.2024
Title **
[English]
AGENTS, COMPOSITIONS, AND METHODS FOR SUPPORTING BEHAVIOURAL DEVELOPMENT
[French]
AGENTS, COMPOSITIONS ET PROCÉDÉS DE SOUTIEN DE DÉVELOPPEMENT COMPORTEMENTAL
Applicants **
SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Inventors
RAJHANS, Purva
SCHNEIDER, Nora
HAUSER, Jonas
ZHU, Hongtu
LI, Tengfei
CHO, Seoyoon
LIN, Weili
Priority Data
23154263.0
31.01.2023
EP
63/462,621
28.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2216 | |
| EPO | Filing, Examination, Granting | 8731 | |
| Japan | Filing, Examination, Granting | 2233 | |
| South Korea | Filing, Examination, Granting | 2143 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,063
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to one or more human milk oligosaccharides (HMOs) for use in supporting behavioural development in a subject, wherein the one or more HMOs comprise or consist of: (a) lacto-N-difucohexaose I (LNDFHI); and/or (b) 2'-fucosyllactose (2'FL), 3- fucosyllactose (3FL), lactodifucotetraose (LDFT), lacto-N-fucopentaose II (LNFPII), lacto-N- fucopentaose I (LNFP-I), lacto-N-fucopentaose III (LNFP-III), lacto-N-difucohexaose I (LND- I), monofucosyl-lacto-N-hexaose III (MFLNH-III), lacto-N-fucopentaose V (LNFP-V), lacto-N- neodifucohexaose (LNnDFH) and lacto-N-fucopentaose VI (LNFP-VI).[French]
La présente invention concerne un ou plusieurs oligosaccharides de lait humain (HMO) destinés à être utilisés dans le soutien du développement comportemental chez un sujet, l'HMO ou les HMO comprenant ou consistant en : (a) du lacto-N-difucohexaose I (LNDFHI) ; et/ou (b) du 2'-fucosyllactose (2'FL), du 3-fucosyllactose (3FL), du du lactodifucotétraose (LDFT), du lacto-N-fucopentaose II (LNFPII), du lacto-N-fucopentaose I (LNFP-I), du lacto-N-fucopentaose III (LNFP-III), du lacto-N-difucohexaose I (LND-I), du monofucosyl-lacto-N-hexaose III (MFLNH-III), du lacto-N-fucopentaose V (LNFP-V), du lacto-N-néodifucohexaose (LNnDFH) et du lacto-N-fucopentaose VI (LNFP-VI).